2017
DOI: 10.1186/s13287-017-0473-x
|View full text |Cite
|
Sign up to set email alerts
|

Cardiotoxicity evaluation using human embryonic stem cells and induced pluripotent stem cell-derived cardiomyocytes

Abstract: BackgroundCardiotoxicity remains an important concern in drug discovery. Human pluripotent stem cell-derived cardiomyocytes (hPSC-CMs) have become an attractive platform to evaluate cardiotoxicity. However, the consistency between human embryonic stem cell-derived cardiomyocytes (hESC-CMs) and human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) in prediction of cardiotoxicity has yet to be elucidated.MethodsHere we screened the toxicities of four representative drugs (E-4031, isoprenaline, q… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

1
13
0
1

Year Published

2018
2018
2022
2022

Publication Types

Select...
8
2

Relationship

1
9

Authors

Journals

citations
Cited by 28 publications
(15 citation statements)
references
References 22 publications
(18 reference statements)
1
13
0
1
Order By: Relevance
“…Cardiotoxicity is still one of the primary factors restricting the development of drugs. Drug development is a time-consuming and expensive process, and past statistics show that up to 90% of compounds that passed pre-clinical screening were terminated in a clinical trial, with approximately 45% of those failures being due to cardiotoxicity [1]. In addition, many drugs that were originally on the market have been withdrawn due to clinical cases of cardiotoxicity.…”
Section: Introductionmentioning
confidence: 99%
“…Cardiotoxicity is still one of the primary factors restricting the development of drugs. Drug development is a time-consuming and expensive process, and past statistics show that up to 90% of compounds that passed pre-clinical screening were terminated in a clinical trial, with approximately 45% of those failures being due to cardiotoxicity [1]. In addition, many drugs that were originally on the market have been withdrawn due to clinical cases of cardiotoxicity.…”
Section: Introductionmentioning
confidence: 99%
“…Due to the high incidence of drug-induced heart failure and irreversible arrhythmia, the pre-clinical evaluation of the cardiotoxicity of drugs is important ( 23 ). However, efficient approaches to evaluate the cardiotoxicity of traditional or novel treatments have been lacking.…”
Section: Discussionmentioning
confidence: 99%
“…Cardiac toxicity is one of the major factors affecting success in drug tests in clinical studies [1]. In total, 90% of drugs that enter clinical trials fail to commercialize owing to their toxic side effects on the heart [2]. Hence, development of such techniques that can measure electrophysiology and contraction force of cardiomyocytes is of critical importance.…”
Section: Introductionmentioning
confidence: 99%